Introduction
The genitourinary syndrome of menopause (GSM) is a collection of chronic urogenital symptoms and signs associated with a decrease in sex steroids, mainly attributed to declining estrogen, as well as androgens.1–3 The term GSM was adopted in 2014 as a more acceptable term to patients that is also more inclusive and scientifically accurate than previously used nomenclature such as vulvovaginal atrophy and atrophic vaginitis.3–5 Importantly, GSM extends beyond symptoms affecting the vulva and vagina to include all tissues that comprise the female genitourinary tract and are susceptible to estrogen deficiency, including the labia, urethra, and bladder.5 Up to 87% of postmenopausal women are estimated to have GSM symptoms during their lifetime, and the condition tends to be progressive in nature with increasing prevalence and severity paralleling the time since the menopause transition.6,7 Common symptoms of GSM include vaginal dryness, irritation, itching, and dyspareunia, as well as urinary urgency, frequency, dysuria, and increased risk of urinary tract infections (UTIs).1,6–8 GSM can have a profound impact on an individual’s physical and psychosocial functioning and quality of life, including their sexual function, self-perception, and relationships.9–11 Indeed, surveys among menopausal women with GSM have consistently reported significantly lower scores on ratings of emotional well-being, sexual functioning, self-concept and body image compared to menopausal women without GSM.12–15
First line treatment for GSM includes vaginal lubricants and moisturizers with appropriate pH and an osmolality of 1200 mOSM or less particularly when symptoms are limited to vaginal dryness and/or dyspareunia.1,8 The recommended second-line therapies for moderate-to-severe GSM are local vaginal hormones, either estrogen or dehydroepiandrosterone (DHEA), which can be administered as creams, tablets, inserts, or sustained-release rings, as well as ospemifene, an oral selective estrogen receptor modulator (SERM).1,8 Systemic menopausal hormone therapy, consisting of estrogen with the addition of a progestogen for endometrial protection in women with an intact uterus, is broadly indicated for the management of menopausal symptoms such as hot flushes and the prevention of osteoporosis, whereas local treatment consisting of low-dose vaginal hormone therapy (HT) is preferred for the treatment of GSM in the absence of systemic menopausal symptoms.16
Despite the availability of evidence-based treatments for GSM with demonstrated effectiveness and safety in clinical trials, real-world evidence collected from broader patient populations encountered in routine clinical practice from data sources such as registries, observational cohorts, and surveys suggests that a substantial proportion of patients do not seek treatment or are not prescribed vaginal HT.17–20 In a recent Canadian survey of 529 postmenopausal patients referred to a specialized menopause clinic, 74% reported bothersome vaginal symptoms and 42% reported moderate-to-severe bladder symptoms, yet only 10.9% of respondents had been prescribed a vaginal HT prior to referral.17 Similarly, a US retrospective claims-based study found that only 9.0% of women with a diagnosis of GSM filled a prescription for vaginal HT.21
The most commonly prescribed therapies for GSM include systemic HT, estradiol tablets, conjugated equine estrogen cream, and DHEA, with relatively few women prescribed estradiol ring or estrone vaginal cream.17 Factors associated with a higher likelihood of being prescribed vaginal HT include older age and being referred to a gynecologist with longer time in practice,17 suggesting that guideline-recommended preferred treatments for GSM are not being routinely offered to women with GSM. This indicates a potential knowledge gap among healthcare providers about the management of GSM and/or a reluctance of women and providers to proactively discuss GSM.17,21 In addition to under-recognition and under-treatment of GSM, other important management gaps include limited patient awareness of GSM symptoms as separate from normal aging, incomplete efficacy of available treatments in some patients, and inequitable access to care.1,6,15,22–24
The goals of this real-world study were to examine current practice patterns and perceptions related to vaginal HT for the management of GSM in Canada from both patient and gynecologist perspectives and to better understand gaps in the optimal management of GSM.
Materials and Methods
PRIME (PRactice assessment to Improve outcomes in Menopausal patiEnts) was a real-world, noninterventional, Canadian, survey-based quality assessment and improvement initiative. Canadian gynecologists with a menopause-focused practice were invited by Email to participate by the study’s scientific steering committee (A.K.S. and C.B.). Participating gynecologists completed a survey assessing their practice characteristics and approach to GSM management, and each gynecologist identified 10 consecutive patients with GSM to participate.
Patients selected for inclusion had a diagnosis of GSM and were either eligible for vaginal HT but had not been prescribed this treatment (naïve) or currently being treated with vaginal HT (on-treatment). Patients provided written informed consent to participate before completing an anonymous survey.
The patient surveys included an anonymized patient-reported and a physician-completed section. Patients provided demographic information and details about GSM symptoms including their onset and assessment as well as their knowledge and perceptions about GSM treatment selection and satisfaction. Physicians provided information about their practice (eg, academic or community setting, duration of practice, patient volume, proportion of postmenopausal patients with GSM, utilization of various GSM therapies, factors driving treatment selection, approach to follow-up, assessment of patient satisfaction with treatment, and perceived challenges related to the management of GSM) and specific details about GSM treatment history (eg, type of GSM therapy currently prescribed and future treatment plan for management of GSM).
Patient and physician surveys are available in the Supplemental Material.
The surveys were completed in March–April 2025. The data were analyzed using descriptive statistics. Subgroup comparisons were analyzed using Chi-square tests with significance defined as <0.05, and nominal P-values are reported.
Physician recruitment was limited to 15 participants with a total patient population of no more than 150 (ie, 75 patients in each cohort). The study was approved by an independent central ethics review board (Advarra IRB #Pro00084793) and complies with the Declaration of Helsinki.
Results
Gynecologist Respondents
Practice Characteristics
Thirteen gynecologists participated in the survey. Most were located in Ontario (54%), practiced in a community setting (77%), and had been practicing for ≥15 years (69%) (Table 1). Based on the gynecologists’ estimates of postmenopausal patients in their practices, the mean proportion referred for GSM was 46.5% and the mean proportion with moderate-to-severe GSM was 47.7%.Table 1Practice Characteristics of Participating GynecologistsCharacteristicsGynecologists (N=13)Regional distribution of practices, n (%) British Columbia2 (15) Ontario7 (54) Quebec3 (23) New Brunswick1 (8)Practice setting, n (%) Academic or university-affiliated practice3 (23) Community practice10 (77)Years in practice, n (%) <50 5–154 (31) ≥159 (69)Estimated proportion of postmenopausal patients in practice referred for management of GSM or related symptoms Mean (SD)46.5 (22.5) Median (range)50.0 (10.0–80.0)Estimated proportion of postmenopausal patients in practice with moderate to severe GSM Mean (SD)47.7 (19.8) Median (range)50.0 (20.0–75.0)Abbreviations: GSM, genitourinary syndrome of menopause; SD, standard deviation.
Prescription and Treatment Patterns of GSM Therapies
The most commonly prescribed vaginal HT formulations based on mean estimates of the gynecologists’ prescribing patterns were estrone/conjugated estrogen creams (35% of patients), estradiol inserts (26%), and estradiol tablets (20%) (Figure 1). Vaginal non-HT options included lubricants (31%) and moisturizers (18%). Figure 1Mean percentage of patients treated with various GSM therapies across gynecologist respondents’ practices (N=13)a. aMean percentage of patients was calculated using individual responses from each gynecologist for estimated percentage of patients with GSM they treat with each type of therapy in their practice.A horizontal bar graph showing mean percentage of patients treated with GSM therapies.Abbreviations: DHEA, dehydroepiandrosterone; GSM, genitourinary syndrome of menopause; HT, hormone therapy; SERM, selective estrogen receptor modulator.
The mean and median proportions of patients remaining on vaginal HT based on gynecologists’ estimates were 67% and 75%, respectively, at 1 year and 49% and 50%, respectively, at 2 years.
Common driving factors for selection of vaginal HT formulations based on gynecologist responses are presented in Table 2. Top driving factors by type of vaginal HT included applicator-free convenience/comfort for estradiol inserts and rings, patient preference for estradiol tablets and estrone/estrogen creams, cost/affordability and coverage by insurance (public or private) for estradiol inserts and estrogen creams, and ease of use for estradiol tablets, DHEA ovules, and estradiol rings. Unlike other formulations, selection of DHEA ovules was primarily driven by their androgen action on vaginal tissue and low risk of systemic absorption.
Frequency of administration was only a top driving factor for estradiol rings and minimal mess/residual discharge was only a top factor for estradiol tablets.Table 2Factors Driving Selection of Different Vaginal HT Formulations for the Treatment of GSM Among Participating Gynecologists (N=13)aDriving factors, n (%)Vaginal HT typeEstrogen creamsEstradiol insertsEstradiol tabletsDHEA ovulesEstradiol ringsApplicator-free convenience and comfortN/A12 (92)N/A1 (8)6 (46)Cost/affordability10 (77)5 (38)5 (38)2 (15)0Coverage by insurance (public/private)9 (69)5 (38)6 (46)2 (15)2 (15)Environmental impact (eg, applicator free)03 (23)000Minimal mess/residual discharge03 (23)7 (54)01 (8)Ease of use3 (23)2 (15)8 (62)4 (31)7 (54)Formulation2 (15)2 (15)2 (15)3 (23)0Frequency of administration2 (15)2 (15)4 (31)2 (15)7 (54)Discretion (eg, can be used at any time of day)01 (8)3 (23)00Location and type of symptoms4 (31)1 (8)1 (8)3 (23)2 (15)Low risk of systemic absorption01 (8)1 (8)4 (31)0Patient preference10 (77)1 (8)7 (54)2 (15)4 (31)Gynecological history (eg, pelvic organ prolapse)2 (15)0004 (31)No effect on breast stimulation0002 (15)0Rapid onset0001 (8)0Androgen action on vaginal tissueN/AN/AN/A9 (69)N/AOtherN/A1 (8)bN/A4 (31)c2 (15)dNotes: aRespondents were asked to select the top 3 factors driving treatment selection for each treatment type. The 3 factors selected by the most respondents for each treatment type are bolded, bOther driving factors included potential bladder support (n=1), cOther driving factors included treatment failure with vaginal estrogen (n=2), contraindications to estrogen (n=1), and decreased libido (n=1), dOther driving factors included pessary use (n=2).Abbreviations: DHEA, dehydroepiandrosterone; GSM, genitourinary syndrome of menopause; HT, hormone therapy; N/A, not applicable.
Although most gynecologists (54%) indicated there were no specific medical conditions (ie, comorbidities/contraindications) that would prevent them from prescribing vaginal HTs for GSM management, the main medical conditions that impact their prescribing included endometrial hyperplasia (23%), breast cancer (personal or family history; 23%), and gynecologic cancer (15%).
GSM Management
Most of the gynecologists (77%) schedule follow-up visits with their patients after initiating GSM treatment, usually after 2–3 months on treatment (80%). Those who do not schedule follow-up visits ask patients to call if they are unsatisfied or assess treatment satisfaction at the patient’s next annual/biennial appointment. Most of the gynecologists (69%) document patient satisfaction with GSM treatment in the patient’s chart based on informal conversation with the patient (ie, without the use of validated instruments/tools).
When asked about the greatest challenges in the management of GSM, the most common responses involved patient awareness/education-related challenges (62%) such as black box warnings/product monograph information for vaginal estrogen products, patient-perceived risks of breast cancer associated with HT use, and taboos associated with GSM and its treatment. Adherence/compliance issues were also identified (38%), predominantly involving the need for long-term treatment given the chronic nature of GSM and patient adherence to/compliance with prescribed dosing regimens.
Patient Respondent Characteristics
The naïve cohort included 54 patients who were eligible for but had not been treated with a vaginal HT, and the on-treatment cohort included 65 patients who were currently on a vaginal HT (Table 3). The mean age in both cohorts was approximately 63 years, and most patients had private insurance coverage (naïve: 52%; on-treatment: 57%). The onset of menopause occurred ≥5 years ago for most patients in the naïve cohort (76%), and nearly half first experienced GSM symptoms ≥5 years ago (46%), although most had been diagnosed with GSM in the last 0–6 months (52%).
In the on-treatment cohort, 55% of patients had received 1 prior vaginal HT and 45% had received ≥2 prior vaginal HTs, and 65% had been on their current treatment for ≥6 months.Table 3Demographics of Patients with GSM Who Were Eligible for but Were Not Yet Receiving Vaginal HT (Naïve) or Were Currently Treated with Vaginal HT (on-Treatment)CharacteristicsNaïveOn-treatment(N=54)(N=65)Age, years, mean (SD)63.3 (9.6)63.4 (10.7)Type of insurance coverage, n (%) Public (government-funded)20 (37)21 (32) Private company28 (52)37 (57) None6 (11)7 (11)Time since onset of menopause, n (%) <1 year3 (6)- 1–2 years4 (7)- 3–4 years6 (11)- ≥5 years41 (76)-Time since GSM symptom onset, n (%) 0–6 months8 (15)- 7–12 months3 (6)- 1–2 years11 (20)- 3–4 years7 (13)- ≥5 years25 (46)-Time since GSM diagnosis, n (%) 0–6 months28 (52)- 7–12 months4 (7)- 1–2 years8 (15)- 3–4 years3 (6)- ≥5 years11 (20)-Type of provider who first diagnosed GSM, n (%) Gynecologist45 (83)- Primary care physician9 (17)-Time since last physical examination of the vagina, months Mean (SD)15.4 (30.0)- Median (range)3.6 (0.2–185.7)-Number of prior vaginal HTs received, n (%) 1-36 (55) ≥2-29 (45)Duration of use of current vaginal HT, n (%) ≤1 month-3 (5) 2–3 months-12 (18) 4–5 months-8 (12) ≥6 months-42 (65)Frequency of use of current vaginal HT, n (%) Daily-11 (17) Twice per week-40 (62) Three times per week-3 (5) Weekly-6 (9) Othera-5 (8)Notes: aOther included every 10 days (n=1 [2%]) and every 3 months (n=4 [6%]).Abbreviations: GSM, genitourinary syndrome of menopause; HT, hormone therapy; SD, standard deviation.
Naïve Cohort: Patients Not on Vaginal HT at Time of Consult
GSM Symptoms and Important Factors in Treatment Selection
The most common GSM symptoms in the naïve cohort were vaginal discomfort, dryness, itching, and burning (61% of patients) and pain during sexual intercourse (50%) (Figure 2). In a subgroup analysis of GSM symptoms by age (<60 vs ≥60 years), changes in sexual function were significantly more common in younger patients (54% vs 27%; P = 0.04) (see Supplemental Material, Table S1). Figure 2GSM symptoms experienced by patients in the naïve cohort at the time of survey completion (N=54).A horizontal bar graph showing percentages of patients experiencing GSM symptoms.Notes: The naïve cohort includes patients with GSM who were eligible for but not currently on vaginal HT at the time of survey completion. aNeeding to urinate more frequently and/or urgently than usual. bDifficulties with bladder control/leaking. cOther vaginal or urinary symptoms included fissures (n=1), odour (n=1), large prolapse (n=1), bleeding after pessary use/changes (n=1), and prolapse and pessary use (n=1).Abbreviations: GSM, genitourinary syndrome of menopause; HT, hormone therapy; UTI, urinary tract infection.
Based on mean patient rankings of factors impacting treatment selection, the most important factors were ease of use, onset of action, and low risk of systemic hormone absorption (Figure 3). Figure 3Mean relative importance of factors for GSM treatment selection from the perspective of patients in the naïve cohort (N=54).A horizontal bar graph showing mean relative importance of factors for GSM treatment selection.Notes: The naïve cohort includes patients with GSM who were eligible for but not currently on vaginal HT at the time of survey completion.Abbreviations: GSM, genitourinary syndrome of menopause; HT, hormone therapy.
Current GSM Therapy and Initiation of Vaginal HT
In the naïve cohort, the most common GSM therapies were vaginal lubricants (33%), vaginal moisturizers (24%), and systemic HT (17%), with 33% of patients not receiving any GSM therapy (Figure 4A). After consultation, 96% of the patients had a GSM treatment plan change, including 78% of patients initiating vaginal HT (Figure 4B). Estradiol inserts (33%), estrone/estrogen creams (19%), and DHEA ovules (19%) were the most common vaginal HTs initiated (Figure 4C).
In a subgroup analysis of newly initiated vaginal HTs by insurance coverage type, a higher proportion of patients with private insurance (vs public) initiated DHEA ovules (29% vs 5%; P = 0.04) (see Supplemental Material, Table S2), which is not a publicly reimbursed treatment in Canada. Figure 4Patient-reported (A) current GSM therapy (N=54), (B) changes to the GSM treatment plan (N=54)*, and (C) breakdown of vaginal HTs initiated in the naïve cohort (N=42).Image A: Horizontal bar chart showing patient treatment percentages. Categories: Vaginal lubricant (33%), Vaginal moisturizer (24%), Systemic HT (17%), Oral SERM (2%), Other (6%), None (33%).
Legend: Vaginal non HT, Vaginal HT, Oral/systemic HT. Image B: Horizontal bar chart showing treatment initiation percentages. Categories: Initiate vaginal HT (78%), Initiate vaginal moisturizer (20%), Initiate vaginal lubricant (19%), Initiate systemic HT (4%), Systemic HT dose/freq change (4%), Other change (2%), No change (4%).
Image C: Horizontal bar chart showing initiated vaginal treatment percentages. Categories: Vaginal estradiol insert (43%), Vaginal estrone/estrogen cream (24%), Vaginal DHEA ovules (24%), Vaginal estradiol tablet (7%), Vaginal estradiol ring (0%), Multiple (2%).A set of three horizontal bar charts showing GSM therapies, treatment plan changes and vaginal HT types initiated.Notes: The naïve cohort includes patients with GSM who were eligible for but not currently on vaginal HT at the time of survey completion. *More than one response could be selected thus total responses >100%. aOther current GSM therapies included local HT (n=2) and mirabegron (n=1). bOther change included fezolinetant (n=1). cVaginal estradiol ring was on backorder from March11 to April2025 (survey completion was March through April2025). dOne patient was initiating both estrone cream and estradiol insert.Abbreviations: DHEA, dehydroepiandrosterone; freq, frequency; GSM, genitourinary syndrome of menopause; HT, hormone therapy; SERM, selective estrogen receptor modulator.
On-Treatment Cohort: Patients Currently on Vaginal HT
Patient Perceptions of Current Vaginal HT
In the on-treatment cohort, 83% of patients reported using their vaginal HT as directed ≥80% of the time. Most patients (78%) perceived their current vaginal HT as somewhat/very effective for GSM symptom management; 8% considered their current treatment not very effective or not effective at all (Figure 5A). The most frequently reported issues with patients’ current vaginal HT were messiness (22%), no vulvar symptom improvement (15%), cost/affordability (14%), and tablet incompletely dissolved (9%), with 35% of patients reporting no issues with their current treatment (Figure 5B).
Most patients (77%) were somewhat/very satisfied with their current therapy’s ease of use, 11% were neutral, 12% were somewhat dissatisfied, and none were very dissatisfied (Figure 5C). Among patients using a vaginal HT requiring an applicator (N=52), 66% found the applicator somewhat/very comfortable and 12% found it somewhat/very uncomfortable (Figure 5D). Figure 5Patient perceptions of current vaginal HT in the on-treatment cohort (N=65), including (A) effectiveness for GSM symptom management, (B) issues experienced, (C) satisfaction with ease of use, and (D) comfort using applicator.Image A: Horizontal bar chart showing treatment effectiveness.
X-axis: Percentage of patients (0-100%). Y-axis: Very effective 43%, Somewhat effective 35%, Neither 14%, Not very effective 6%, Not effective 2%. Image B: Horizontal bar chart showing treatment issues.
X-axis: Percentage of patients (0-100%). Y-axis: Messiness 22%, No improvement 15%, Cost 14%, Incomplete dissolution 9%, Timing inconvenience 6%, Insurance 6%, Side effects 5%, Painful application 3%, Sexual interference 2%, Other 11%, None 35%. Image C: Horizontal bar chart showing satisfaction levels.
X-axis: Percentage of patients (0-100%). Y-axis: Very satisfied 42%, Somewhat satisfied 35%, Neutral 11%, Somewhat dissatisfied 12%, Very dissatisfied 0%. Image D: Horizontal bar chart showing comfort levels.
X-axis: Percentage of patients (0-100%). Y-axis: Very comfortable 33%, Somewhat comfortable 33%, Neutral 23%, Somewhat uncomfortable 10%, Very uncomfortable 2%.4 bar charts on patient views of vaginal HT: effectiveness, issues, ease, comfort.Notes: The on-treatment cohort includes patients with GSM who were currently on vaginal HT at the time of survey completion. aFor example, having to use it at aspecific time. bNoted side effects included burning, insomnia, cramping, and yeast infection symptom. cFor example, when using an applicator. dOther issues included availability of product (n=3), having to urinate during the night (n=1), concerns about amount of plungers wasted (n=1), external use only (n=1), and residual pain (n=1).Abbreviations: GSM, genitourinary syndrome of menopause; HT, hormone therapy.
Changes to GSM Therapy
Overall, 77% of patients would consider switching vaginal HTs, most commonly for reasons related to less mess/residual discharge (29%) and easier application (28%) (Figure 6). After consultation with their gynecologist, 43% of patients switched vaginal HTs and 46% of patients had no change to their treatment plan (Figure 7A). Among vaginal HT switchers (N=28), 43% switched to estradiol inserts, 36% to DHEA ovules, 11% to an estrone/estrogen cream, and 7% to estradiol tablets (Figure 7B).
Figure 6Factors that would make patients consider switching vaginal HTs in the on-treatment cohort (N=65).A horizontal bar graph showing reasons patients would consider switching vaginal hormone therapies.Notes: The on-treatment cohort includes patients with GSM who were currently on vaginal HT at the time of survey completion. aFor example, without an applicator. bFor example, can be used any time ofday. cOther factors included working better (n=2), availability (n=1), better treatment of vulva (n=1), bladder improvements (n=1), lack of ability to physically insert products (n=1), loss of effectiveness (n=1), libido (n=1), and certainty of benefits and underlying cause of symptoms (n=1).Abbreviations: GSM, genitourinary syndrome of menopause; HT, hormone therapy; UTI, urinary tract infection.Figure 7Characteristics of GSM treatment plan in the on-treatment cohort, including (A) changes made to treatment (N=65) and (B) breakdown of new vaginal HT among switchers (N=28).Image A shows a horizontal bar chart with the x-axis labeled ′Percentage of patients′ (0% to 100%). The y-axis includes: Switch vaginal hormone therapy (43%), Initiate vaginal moisturizer (12%), Initiate lubricant (11%), Discontinue current vaginal hormone therapy (5%), Initiate oral selective estrogen receptor modulator (5%), Initiate systemic hormone therapy (3%), Change current vaginal hormone therapy dose/frequency (2%), Switch systemic hormone therapy (2%), Other change (5%), No change (46%). Image B displays another horizontal bar chart with the same x-axis label.
The y-axis lists: Vaginal estradiol insert (43%), Vaginal dehydroepiandrosterone ovules (36%), Vaginal estrone/estrogen cream (11%), Vaginal estradiol tablet (7%), Multiple (4%), Vaginal estradiol ring (0%). A legend categorizes therapies into Vaginal non-hormone therapy, Vaginal hormone therapy and Oral/systemic hormone therapy.A pair of horizontal bar charts showing treatment changes and new vaginal hormone therapy choices.Notes: The on-treatment cohort includes patients with GSM who were currently on vaginal HT at the time of survey completion. aOther changes included switch from KY jelly to menopausal formulation (n=1), switch in vaginal moisturizers (n=1), and decreasing frequency of vaginal moisturizer use since starting vaginal estrogen cream (n=1). bOne patient was initiating both estrone cream and estradiol insert.Abbreviations: freq, frequency; GSM, genitourinary syndrome of menopause; HT, hormone therapy; SERM, selective estrogen receptor modulator.
Among patients who were dissatisfied with the ease of use of their current GSM therapy (n=8), all discontinued the treatment and/or initiated a new treatment. Changes to the GSM treatment plan were mixed for patients who felt neutral about the ease of use of their current GSM therapy (n=7; 2 had no change, 1 discontinued their current vaginal HT, and 3 switched vaginal HTs).
Discussion
This survey highlights real-world treatment patterns and factors driving treatment selection for GSM in Canada as well as patient satisfaction with vaginal HT. Overall, gynecologists and patients were largely aligned on the factors that drive their selection of vaginal HT for the management of GSM. Notably, convenience and ease of use, low mess or residual discharge, and cost are the main drivers of vaginal HT selection from both the physician and patient perspectives.
Two factors that were ranked relatively higher by patients than by physicians were speed of onset of action and low risk of systemic absorption. These observations highlight the importance of shared decision-making to ensure that factors that are important to both patients and healthcare providers are taken into consideration when making individualized treatment decisions for the management of GSM.
There was an apparent disconnect between gynecologists’ perception of patient compliance to GSM treatment and patients’ self-reported adherence. Gynecologists identified compliance as one of the greatest challenges in managing GSM, whereas 83% of patients in the on-treatment cohort reported taking their vaginal HT according to package instructions at least 80% of the time and only 10% stated that they use their vaginal HT at an off-label dosing frequency (ie, weekly or every 10 days). This mismatch in physician and patient perceptions about adherence is aligned with the findings of a Spanish survey, which reported that gynecologists estimate that vaginal HT is taken by patients only about 50% of the time.25 These observations highlight the need for effective communication between gynecologists and their patients.
According to a US study, better physician counselling and communication about vaginal HT are both critical factors to support improved patient adherence.26
The key factors associated with patient satisfaction or dissatisfaction with vaginal HT were largely similar in that positive perception of a factor would drive satisfaction, whereas negative perception of the same factor would drive dissatisfaction. For example, high perceived efficacy was the top patient-reported reason for satisfaction with treatment, whereas low perceived efficacy was the top reason for dissatisfaction. Similarly, the top factors associated with patient-reported dissatisfaction with their current vaginal HT mirrored the reasons that patients would consider switching therapies.
Indeed, all patients in the on-treatment cohort who were dissatisfied with the ease of use of their current vaginal HT discontinued it or switched to another vaginal HT.
A non-negligible proportion of patients in the on-treatment cohort were neutral or dissatisfied with the perceived effectiveness (22%), ease of use (23%), and/or comfort of application (45%) of their current vaginal HT, and most (65%) had experienced issues with their treatment such as messiness/residual discharge or incompletely dissolved vaginal tablets. Even among the 46% of patients who had no change in their current GSM treatment regimen, although satisfaction with ease of use was high (93% were somewhat or very satisfied), more than half (53%) experienced at least one issue with their current GSM therapy. These patients could benefit from a dialogue with their gynecologist about alternative treatment options.
However, one-third of participating gynecologists do not routinely assess and document patient satisfaction with treatment during follow-up visits and one-quarter do not schedule a follow-up visit after initiating treatment for GSM, representing a missed opportunity to optimize patient care and outcomes. An American qualitative study in patients using vaginal HT supports the positive impact of better physician counselling and enhanced communication to support the physician-patient relationship and adherence to treatment.26
Observations from the PRIME study highlight the ongoing need for education of both menopause care providers and patients about GSM and its management. Among this group of menopause-focused gynecologists, there were misconceptions about contraindications to vaginal HT, specifically whether it is safe to use in patients with a family history of breast cancer or thrombophlebitis. Systemic HT was taken by 17% of patients with GSM even though its use for GSM in the absence of other menopause symptoms is not routinely recommended.8 It is possible that some patients who were treated with systemic HT for vasomotor symptoms had concomitant GSM that was inadequately controlled.
However, a recent survey of 529 Canadian patients treated in a specialized menopause clinic suggests that patients with vaginal dryness were approximately four times more likely to receive systemic HT than vaginal HT.17 Limited patient awareness and knowledge about GSM underscores the importance of education about GSM as a lifelong condition that can often be adequately managed with local treatment. Risk of systemic absorption of vaginal HT was a top concern among patients even though vaginal HTs are associated with a low risk of absorption and systemic side effects,27,28 suggesting that patients would benefit from the provision of educational resources and reassurance from their gynecologists about the safety of vaginal HT.
The boxed warning about the association between HT and breast cancer, which stems from the Women’s Health Initiative study, remains a barrier to prescribing vaginal HT even though this warning has been removed from product labels in some jurisdictions.29,30 For example, the US Food and Drug Administration recently ruled to remove the boxed warning from all menopausal HTs including vaginal HT.31 Although concerns about vaginal HT safety were not identified as a barrier by patients in this study, participating gynecologists perceive patient concerns about the boxed warning and the breast safety of HT in general as being challenges in the management of GSM. This observation provides further support for the removal of the boxed warning in other jurisdictions in order to provide symptomatic menopausal women with optimal care. The Canadian Menopause Society welcomed the decision by the FDA to remove the boxed warning from HT product labels and continues to engage with Health Canada in discussions regarding up-to-date evidence and product labelling.32
A notable strength of this study is that both physicians and their patients were surveyed about their perceptions of GSM management, thus reflecting the important paradigm of shared decision-making. Two cohorts of patients were included and analyzed separately, allowing for distinct but complementary insights to be collected from patients eligible for but not currently receiving vaginal HT as well as those currently treated with vaginal HT. Three-quarters of participating gynecologists had been practicing for 15 or more years, and all had been practicing for 5 or more years, underscoring a high level of experience among physician respondents; however, the perspectives of gynecologists who are newer to practice could be different and their absence potentially contributes to responder bias.
Other limitations of this study include selection bias since patients were identified by their gynecologist to participate. Only patients consulting a gynecologist with a menopause-focused practice were recruited, limiting the generalizability of the study findings to the wider population of Canadian patients with GSM, including those who are managed in the primary care setting. The number of gynecologists who were approached but declined to participate was not collected.
There was no objective tool used by gynecologists to evaluate vaginal health and thus categorize treatment success or failure to formally guide the decision to make changes to the patient’s GSM treatment plan. Finally, the statistics were mostly descriptive in nature.
Conclusions
This study highlights gaps and opportunities to improve the current management of GSM in Canada. Overall, many patients are satisfied with the effectiveness and ease of use of vaginal HT, and gynecologists and patients are generally aligned on factors that drive vaginal HT treatment selection. Nonetheless, patient education about GSM and its treatment, as well as additional education for gynecologists regarding the importance of open communication and follow-up, are important gaps in care that should be addressed.
Tools to help gynecologists and patients engage in discussions about treatment selection as well as satisfaction and adherence could help support shared decision-making and the delivery of patient-centered care. Further research investigating the perceptions and treatment patterns of a broader population of healthcare providers managing menopause and patients with GSM is warranted.